PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas

Summary

This phase I trial is studying the side effects and best dose of PXD101 and bortezomib in treating patients with advanced solid tumors or lymphomas. PXD101 and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PXD101 may also cause cancer cells to look more like normal cells, and to grow and spread more slowly. Giving PXD101 together with bortezomib may kill more cancer cells.

Timeline

Start

2006-03

Primary completion

2010-01

Completion

—

Drugs

Indications